BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 2015;16:2679-88. [DOI: 10.1517/14656566.2015.1109631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Cusato J, De Nicolò A, Boglione L, Favata F, Ariaudo A, Pinna SM, Carcieri C, Guido F, Cariti G, Di Perri G, D'Avolio A. Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. Pharmacogenomics 2018;19:701-7. [PMID: 29790402 DOI: 10.2217/pgs-2018-0009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Peng Q, Li K, Cao MR, Bie CQ, Tang HJ, Tang SH. Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis. Springerplus 2016;5:1569. [PMID: 27652142 DOI: 10.1186/s40064-016-3218-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Yahya G, Hashem Mohamed N, Pijuan J, Seleem NM, Mosbah R, Hess S, Abdelmoaty AA, Almeer R, Abdel-Daim MM, Shulaywih Alshaman H, Juraiby I, Metwally K, Storchova Z. Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. Microb Biotechnol 2021. [PMID: 34378349 DOI: 10.1111/1751-7915.13904] [Reference Citation Analysis]